Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Menu

    Nalbuphine Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 7,591Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Trevi Therapeutics to Present Phase 2a RIVER Trial Data at ERS
    Trevi Therapeutics to Present Phase 2a RIVER Trial Data at ERS

    18 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-two-posters-from-the-phase-2a-river-trial-data-will-be-featured-at-the-european-respiratory-society-ers-congress-2025-302559765.html

    PR NEWSWIRE
    18 Sep 2025
    Share Share
    Trevi Therapeutics Reports Q2 2025 Financials, Updates
    Trevi Therapeutics Reports Q2 2025 Financials, Updates

    08 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/trevi-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-updates-302524769.html

    PR NEWSWIRE
    08 Aug 2025
    Share Share
    Trevi Raises $115M in Offering, Underwriters Fully Exercise
    Trevi Raises $115M in Offering, Underwriters Fully Exercise

    05 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-closing-of-115-million-underwritten-offering-and-full-exercise-by-underwriters-of-option-to-purchase-additional-shares-302474714.html

    PR NEWSWIRE
    05 Jun 2025
    Share Share
    Trevi Therapeutics Plans Public Offering of Common Stock
    Trevi Therapeutics Plans Public Offering of Common Stock

    02 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-proposed-public-offering-of-common-stock-302471111.html

    PR NEWSWIRE
    02 Jun 2025
    Share Share
    Trevi Therapeutics to Participate in Upcoming June Conferences
    Trevi Therapeutics to Participate in Upcoming June Conferences

    28 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-june-conferences-302467673.html

    PR NEWSWIRE
    28 May 2025
    Share Share
    Trevi Shares New Phase 2a Data on Haduvio for Chronic Cough
    Trevi Shares New Phase 2a Data on Haduvio for Chronic Cough

    20 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-additional-analyses-from-phase-2a-river-trial-of-haduvio-in-patients-with-refractory-chronic-cough-302459653.html

    PR NEWSWIRE
    20 May 2025
    Share Share